FDA Approves New Uses For Evista - Drug Reduces Risk Of Invasive Breast Cancer In Postmenopausal
FDA Approves New Uses For Evista - Drug Reduces Risk Of Invasive Breast Cancer In Postmenopausal
|
The U.S. Food and Drug Administration approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. Evista is only the second drug approved to reduce the risk of breast cancer. [click link for full article] |
read more...
News entry number 2298 added on Sep 18, 2007 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- LA BioMed Research Finds Simpler Way To Determine Breast Cancer Risk In Postmenopausal Women
- More women face breast cancer risk
- Birth control reduces risk of certain cancers: study
- Older women unaware of rising breast cancer risk
- Women stop taking breast cancer drugs due to aches and pains: study
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Cancer risk from the Pill
- Purdue Researchers Develop Non-Invasive Cancer Test
- IPSOGEN And DNAVision Enter In Agreement To Offer In Vitro Diagnostic Tests For Breast Cancer
News Categories
745
522
479
347
1003
691
279
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Wireless technology hits security budgets
- Google Starts Hosting News on Website
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Google forced to push image in China
- Ho-hum, the guest's another candidate
- Microsoft purchase of RIM nice to consider, but unlikely
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5039
8
621
8
621